英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

reappraise    音标拼音: [r,iəpr'ez]
vt. 重新评估,重新评价

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • GLP-1 Receptor Agonists (GLP-1 RAs) - The National Kidney . . .
    Current guidelines recommend a long-acting GLP-1 RA for adults living with type 2 diabetes and CKD who have not yet reached their diabetes goals with metformin and an SGLT2 inhibitor GLP-1 stands for “glucagon-like peptide-1”
  • 6 things to know about GLP1-RAs and CKD - American Kidney Fund
    In January 2025, an injectable form of a GLP1-RA, semaglutide (Ozempic), was approved to reduce the risk of chronic kidney disease (CKD) worsening in people who also have type 2 diabetes GLP1-RAs act as glucagon-like peptide 1, a hormone that is released when you eat
  • GLP-1 receptor agonists in patients with chronic kidney . . .
    As a result, the 2022 and 2024 KDIGO guidelines for the treatment of CKD in T2DM indicate GLP-1 RAs as third-line antidiabetic drugs to improve glycaemic control when not achieved by metformin and or SGLT2i or if SGLT2i contraindicated [11, 12]
  • GLP-1 Receptor Agonists for CKD: Remaining Issues or Mission . . .
    The US Food and Drug Administration approved the GLP-1 receptor agonist semaglutide to reduce kidney and cardiovascular risk in patients with type 2 diabetes and CKD in January 2025, with data on treatment effects still accumulating
  • New Weight Loss Drugs May Have Cardiorenal Benefits for . . .
    Glycogen-like peptide-1 receptor antagonists (GLP-1 RAs) and sodium glucose contransporter-2 (SGLT2) inhibitors may have cardioprotective effects for patients with chronic kidney disease (CKD), according to Alexander R Chang, MD, MS, a nephrology specialist, in a session at the American Society of Nephrology (ASN) 2023 Kidney Week Annual
  • GLP-1 Medications Their Potential Role in Renal Diseases
    By inhibiting the processes that lead to fibrosis, GLP-1 drugs help protect the kidney’s structural integrity This is critical in preventing the progression of CKD from early stages to end-stage kidney disease (ESKD), which often requires dialysis or kidney transplantation Impact on Cardiovascular Risk
  • Episode 43: Impacts of GLP-1 Receptor Agonists and SGLT-2 . . .
    Classes of drugs such as GLP-1 receptor agonists and SGLT-2 inhibitors have been shown to improve the control of blood glucose, blood pressure, body weight, and reduce the risk of different types of adverse cardiovascular events in diabetic patients, a comorbidity common in patients with chronic kidney disease





中文字典-英文字典  2005-2009